Einar Ottestad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Einar Ottestad has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Amitabh Gulati
Department of Anesthesia and Critical Care, Memorial Sloan Kettering Cancer Center, New York, New York, USA
2 shared publicationsAbdullah Sulieman Terkawi
Division of Pain Medicine, Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University School of Medicine, Palo Alto, California, USA
1 shared publicationAlexander Sable-Smith
Stanford University School of Medicine
1 shared publication- Alice Huai-Yu Li
Department of Anesthesia, Stanford University, Stanford, California, USA
1 shared publication Amit Gulati
Department of Anesthesiology and Critical Care, Memorial Sloan Kettering Cancer Center, New York, New York, USA
1 shared publication- Ankur Patel
Novant Health Spine Specialists, Winston Salem, USA
1 shared publication
Latest Publications
- 20 March 2025
- Published by Springer Nature in International Orthopaedics
- Vol. 49 (5) , 989-996
Nerve stimulation and neuromodulation for painful nerves: a narrative review
Nerve injury primarily leads to neuropathic pain but may also have overlapping elements of nociplastic pain or ongoing nociceptive pain. Electrical stimulation is particularly effective in the treatment of neuropathic pain and may be effective for nociplastic and nociceptive pain. While multiple mechanisms contribute to the analgesic effect of electrical stimulation, the most widely accepted theory for the predominant effect is that of Melzack and Wall’s gate control theory. According to this theory, non-painful sensory input carried by low-threshold large-diameter Aβ fibres disrupt the transmission of pain signals in small pain fibers (Aδ and C fibres). This occurs through the activation of inhibitory interneurons in the dorsal horn, which ultimately blocks pain signal transmission. This theory has been employed for different forms of stimulation, including transcutaneous electrical nerve stimulation (TENS), percutaneous electrical nerve stimulation (PENS), and peripheral nerve stimulation (PNS). Each of these methods offers a different approach to localized stimulation and neuromodulation for the treatment of pain. TENS is a non-invasive technique, that delivers electrical currents via surface electrodes placed on the skin. PENS, in contrast, is a minimally invasive method that applies electrical currents through small needles inserted near a target muscle or neural structure. PNS involves the implantation of temporary or permanent electrodes to deliver electrical stimulation directly to peripheral nerves. These modalities are widely used to manage various pain conditions including non-malignant, chronic musculoskeletal and neuropathic pain, such as chronic low back pain, neck pain, neuropathic pain, myofascial pain, and post-operative pain. TENS is particularly notable as a non-invasive device that is affordable, over-the-counter, self-administered, and nonpharmacological option that does not pose the risk of toxicity or overdose. PENS stands out for its ability to integrate electrical stimulation therapy with electroacupuncture through a minimally invasive technique. PNS, on the other hand, is unique in its capacity to precisely target specific nerves and provide a range of stimulation options for extended treatment durations. This article provides a narrative overview of TENS, PENS and PNS with a particular focus on their application for neuropathic pain management and for athletes. We will review mechanisms of action, indications, diagnostic and treatment algorithms, as well as complications and limitations. The overview concludes with a complex case study demonstrating the use of various electrical stimulation therapies, ultimately to successful pain resolution for the patient.
- 20 March 2025
- Published by Springer Nature in International Orthopaedics
- Vol. 49 (5) , 989-996
Nerve stimulation and neuromodulation for painful nerves: a narrative review
Nerve injury primarily leads to neuropathic pain but may also have overlapping elements of nociplastic pain or ongoing nociceptive pain. Electrical stimulation is particularly effective in the treatment of neuropathic pain and may be effective for nociplastic and nociceptive pain. While multiple mechanisms contribute to the analgesic effect of electrical stimulation, the most widely accepted theory for the predominant effect is that of Melzack and Wall’s gate control theory. According to this theory, non-painful sensory input carried by low-threshold large-diameter Aβ fibres disrupt the transmission of pain signals in small pain fibers (Aδ and C fibres). This occurs through the activation of inhibitory interneurons in the dorsal horn, which ultimately blocks pain signal transmission. This theory has been employed for different forms of stimulation, including transcutaneous electrical nerve stimulation (TENS), percutaneous electrical nerve stimulation (PENS), and peripheral nerve stimulation (PNS). Each of these methods offers a different approach to localized stimulation and neuromodulation for the treatment of pain. TENS is a non-invasive technique, that delivers electrical currents via surface electrodes placed on the skin. PENS, in contrast, is a minimally invasive method that applies electrical currents through small needles inserted near a target muscle or neural structure. PNS involves the implantation of temporary or permanent electrodes to deliver electrical stimulation directly to peripheral nerves. These modalities are widely used to manage various pain conditions including non-malignant, chronic musculoskeletal and neuropathic pain, such as chronic low back pain, neck pain, neuropathic pain, myofascial pain, and post-operative pain. TENS is particularly notable as a non-invasive device that is affordable, over-the-counter, self-administered, and nonpharmacological option that does not pose the risk of toxicity or overdose. PENS stands out for its ability to integrate electrical stimulation therapy with electroacupuncture through a minimally invasive technique. PNS, on the other hand, is unique in its capacity to precisely target specific nerves and provide a range of stimulation options for extended treatment durations. This article provides a narrative overview of TENS, PENS and PNS with a particular focus on their application for neuropathic pain management and for athletes. We will review mechanisms of action, indications, diagnostic and treatment algorithms, as well as complications and limitations. The overview concludes with a complex case study demonstrating the use of various electrical stimulation therapies, ultimately to successful pain resolution for the patient.
- Open Access
- 16 September 2024
- Published by Elsevier in Interventional Pain Medicine
- Vol. 3 (3) , 100436
Superior Cluneal neuralgia—An underappreciated cause of low back pain?
- 16 September 2024
- Published by Elsevier in Interventional Pain Medicine
- Vol. 3 (3) , 100436
Open AccessSuperior Cluneal neuralgia—An underappreciated cause of low back pain?
- 2 December 2023
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 49 (6) , 455-460
Peripheral nerve stimulation for saphenous neuralgia
Background Injury to saphenous nerve branches is frequent during knee surgery and can result in chronic pain. This saphenous neuralgia remains challenging to treat. Peripheral nerve stimulation (PNS) is a new potential non-pharmacologic treatment option. We present our outcomes experience using this technology in 12 patients. Methods We retrospectively reviewed PNS placement for saphenous neuralgia between 2000 and 2022 at a single institution. Demographic information was collected as well as response to the device. Four-question short-form Patient-Reported Outcome Measurement Information System (PROMIS) Scores were collected before and 2 weeks, 6 weeks, and 6 months postprocedure. Specific scores included pain interference and behavior, functional mobility, depression, anxiety, and sleep impairment. Change in pain interference measured by the short-form PROMIS tool at 6 months was chosen as the primary outcome. Results Twelve patients met inclusion criteria, with 10 patients having the full 6-month follow-up. In these 10 patients, the mean change from baseline in the short-form adjusted pain interference score (greater difference means improved pain) at 6 months was 5.8 (SD 6.5). Among all patients, average follow-up was 11.5 months (range 3–35 months). Most patients’ symptoms developed after knee surgery (84%). Prior to PNS, patients underwent other treatments including cryoablation (8%), radiofrequency ablation (16%), saphenous neurectomy (16%), or surgical release of adjacent nerves (25%). Ten patients (83%) reported any improvement in symptoms while two reported no benefit. Complications occurred in four patients (33%). Two patients had the device removed and a third discontinued use. PROMIS Scores for pain, functional mobility, mood, and sleep impairment all improved. Discussion Limited effective treatments exist for saphenous neuralgia. Our case series demonstrates the potential of PNS as a treatment for saphenous neuralgia. Comparative effectiveness studies are warranted to assess whether our effect size is clinically relevant.
- 2 December 2023
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 49 (6) , 455-460
Peripheral nerve stimulation for saphenous neuralgia
Background Injury to saphenous nerve branches is frequent during knee surgery and can result in chronic pain. This saphenous neuralgia remains challenging to treat. Peripheral nerve stimulation (PNS) is a new potential non-pharmacologic treatment option. We present our outcomes experience using this technology in 12 patients. Methods We retrospectively reviewed PNS placement for saphenous neuralgia between 2000 and 2022 at a single institution. Demographic information was collected as well as response to the device. Four-question short-form Patient-Reported Outcome Measurement Information System (PROMIS) Scores were collected before and 2 weeks, 6 weeks, and 6 months postprocedure. Specific scores included pain interference and behavior, functional mobility, depression, anxiety, and sleep impairment. Change in pain interference measured by the short-form PROMIS tool at 6 months was chosen as the primary outcome. Results Twelve patients met inclusion criteria, with 10 patients having the full 6-month follow-up. In these 10 patients, the mean change from baseline in the short-form adjusted pain interference score (greater difference means improved pain) at 6 months was 5.8 (SD 6.5). Among all patients, average follow-up was 11.5 months (range 3–35 months). Most patients’ symptoms developed after knee surgery (84%). Prior to PNS, patients underwent other treatments including cryoablation (8%), radiofrequency ablation (16%), saphenous neurectomy (16%), or surgical release of adjacent nerves (25%). Ten patients (83%) reported any improvement in symptoms while two reported no benefit. Complications occurred in four patients (33%). Two patients had the device removed and a third discontinued use. PROMIS Scores for pain, functional mobility, mood, and sleep impairment all improved. Discussion Limited effective treatments exist for saphenous neuralgia. Our case series demonstrates the potential of PNS as a treatment for saphenous neuralgia. Comparative effectiveness studies are warranted to assess whether our effect size is clinically relevant.
- 20 April 2023
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 48 (6) , 312-318
Role of peripheral nerve stimulation in treating chronic neuropathic pain: an international focused survey of pain medicine experts
Interventional pain management (IPM) options for refractory neuropathic pain (NP) have recently increased with availability of peripheral nerve stimulation (PNS) equipment and expertise. Given a lack of high-quality evidence and guidelines on this topic, we sought to understand the perception of physicians with expertise in treating NP regarding IPM and the role of PNS. We emailed a survey in March 2022 to international NP experts including pain medicine physicians, researchers, and leaders of 11 professional pain societies. No representatives from vendors of PNS systems were included in the design of the survey nor as respondents. Among 24 respondents (67% of those contacted), the distal common peroneal, tibial, and sural nerves were most frequently targeted (60%) with PNS. Persistent postsurgical pain of more than 3 months was the most common indication for PNS (84%). The aggregate NP treatment algorithm in order of median rank was non-opioid medications as first line, IPM including epidural/perineural steroid injections tied with transcutaneous electrical nerve stimulation as second line, pulsed radiofrequency (RF) tied with RF ablation/denervation as third line, temporary then permanent PNS as fourth line, followed by spinal cord stimulation, opioids, cryoablation, botulinum, peripheral nerve field stimulation, intrathecal targeted drug delivery, and others. Before offering PNS, 12 respondents (50%) indicated their preference for trialing non-neuromodulation treatments for 1–3 months. Twenty-two respondents (92%) agreed PNS should be offered early in the treatment of neuropathic pain. The most common barriers to PNS use were cost, lack of high-quality evidence in support of its use, lack of exposure to PNS in training programs, and lack of familiarity with the use of ultrasound guidance. PNS appears to have an increasing role in the treatment of NP but more research is needed on the outcomes of PNS to elucidate its role.
- 20 April 2023
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 48 (6) , 312-318
Role of peripheral nerve stimulation in treating chronic neuropathic pain: an international focused survey of pain medicine experts
Interventional pain management (IPM) options for refractory neuropathic pain (NP) have recently increased with availability of peripheral nerve stimulation (PNS) equipment and expertise. Given a lack of high-quality evidence and guidelines on this topic, we sought to understand the perception of physicians with expertise in treating NP regarding IPM and the role of PNS. We emailed a survey in March 2022 to international NP experts including pain medicine physicians, researchers, and leaders of 11 professional pain societies. No representatives from vendors of PNS systems were included in the design of the survey nor as respondents. Among 24 respondents (67% of those contacted), the distal common peroneal, tibial, and sural nerves were most frequently targeted (60%) with PNS. Persistent postsurgical pain of more than 3 months was the most common indication for PNS (84%). The aggregate NP treatment algorithm in order of median rank was non-opioid medications as first line, IPM including epidural/perineural steroid injections tied with transcutaneous electrical nerve stimulation as second line, pulsed radiofrequency (RF) tied with RF ablation/denervation as third line, temporary then permanent PNS as fourth line, followed by spinal cord stimulation, opioids, cryoablation, botulinum, peripheral nerve field stimulation, intrathecal targeted drug delivery, and others. Before offering PNS, 12 respondents (50%) indicated their preference for trialing non-neuromodulation treatments for 1–3 months. Twenty-two respondents (92%) agreed PNS should be offered early in the treatment of neuropathic pain. The most common barriers to PNS use were cost, lack of high-quality evidence in support of its use, lack of exposure to PNS in training programs, and lack of familiarity with the use of ultrasound guidance. PNS appears to have an increasing role in the treatment of NP but more research is needed on the outcomes of PNS to elucidate its role.
- 1 June 2022
- Published by Springer Nature
- p. 917-925
Ultrasound-Guided Peripheral Nerve Stimulation
- Open Access
- 1 August 2020
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 21 (Supplement) , S1-S2
Advances in Peripheral Nerve Stimulation: More Clinical Options, More Science
While neuromodulation of a peripheral nerve for pain relief is not a novel concept, the explosion of dedicated peripheral nerve stimulation (PNS) technologies has reinvigorated the field of pain medicine. The new percutaneous devices are easily placed without requiring general anesthesia or open peripheral nerve surgery, which greatly expands the pool of potential implanting physicians. The addition of ultrasound to the pain clinician’s armamentarium has improved the ability to diagnose neuropathic pain and the accurate delivery of this technology to the target neural structure. Renewed interest in this field has led to better understanding of the mechanisms involved in PNS and its clinical effect on pain and function. As a result of these advances, pain practitioners around the world are readdressing acute and chronic pain syndromes of peripheral origin with the potential for improved safety and efficacy. Countless hours of work and dedication have resulted in a much-needed supplement reviewing peripheral nerve stimulation in Pain Medicine.
- 1 August 2020
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 21 (Supplement) , S1-S2
Open AccessAdvances in Peripheral Nerve Stimulation: More Clinical Options, More Science
While neuromodulation of a peripheral nerve for pain relief is not a novel concept, the explosion of dedicated peripheral nerve stimulation (PNS) technologies has reinvigorated the field of pain medicine. The new percutaneous devices are easily placed without requiring general anesthesia or open peripheral nerve surgery, which greatly expands the pool of potential implanting physicians. The addition of ultrasound to the pain clinician’s armamentarium has improved the ability to diagnose neuropathic pain and the accurate delivery of this technology to the target neural structure. Renewed interest in this field has led to better understanding of the mechanisms involved in PNS and its clinical effect on pain and function. As a result of these advances, pain practitioners around the world are readdressing acute and chronic pain syndromes of peripheral origin with the potential for improved safety and efficacy. Countless hours of work and dedication have resulted in a much-needed supplement reviewing peripheral nerve stimulation in Pain Medicine.
- Open Access
- 1 August 2020
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 21 (Supplement) , S13-S17
Peripheral Nerve Stimulation for Occipital Neuralgia
Background: Chronic headaches are the second most prevalent disease and second most common cause for years lived with disability worldwide. Occipital neuralgia can cause headaches or be present in addition to other more prevalent causes of headache. If these headaches fail to respond to conservative and pharmacological therapy, physicians proceed to more invasive treatments, starting with infiltration of the greater occipital nerve with local anesthetic with or without corticosteroids, followed by nerve ablation or stimulation. Occipital nerve stimulation gained more popularity as the technology improved and more pain physicians received training on interventional procedures.Methods: In this manuscript, we are presenting our experience with ultrasound-guided implant of occipital nerve stimulators using peripheral nerve stimulator systems. After confirming appropriateness of treatment by a successful occipital nerve block (i.e., resulting in >50% relief in patients’ pain intensity), we implanted five stimulator systems in three patients (two bilateral).Results: We followed these patients for an average of eight months, and the average pain reduction was ∼50%. We did not observe any adverse events during or immediately after surgery. One patient developed an adverse reaction to the adhesive of the battery transmitter, but it was not severe enough to stop her from using the stimulator.Conclusions: Considering the ease of implant and minimal side effects, implant of peripheral nerve stimulators to stimulate the occipital nerve is a promising treatment modality for patients with chronic headache who present with features of occipital neuralgia. However, wider use of this treatment modality is subject to further studies.
- 1 August 2020
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 21 (Supplement) , S13-S17
Open AccessPeripheral Nerve Stimulation for Occipital Neuralgia
Background: Chronic headaches are the second most prevalent disease and second most common cause for years lived with disability worldwide. Occipital neuralgia can cause headaches or be present in addition to other more prevalent causes of headache. If these headaches fail to respond to conservative and pharmacological therapy, physicians proceed to more invasive treatments, starting with infiltration of the greater occipital nerve with local anesthetic with or without corticosteroids, followed by nerve ablation or stimulation. Occipital nerve stimulation gained more popularity as the technology improved and more pain physicians received training on interventional procedures.Methods: In this manuscript, we are presenting our experience with ultrasound-guided implant of occipital nerve stimulators using peripheral nerve stimulator systems. After confirming appropriateness of treatment by a successful occipital nerve block (i.e., resulting in >50% relief in patients’ pain intensity), we implanted five stimulator systems in three patients (two bilateral).Results: We followed these patients for an average of eight months, and the average pain reduction was ∼50%. We did not observe any adverse events during or immediately after surgery. One patient developed an adverse reaction to the adhesive of the battery transmitter, but it was not severe enough to stop her from using the stimulator.Conclusions: Considering the ease of implant and minimal side effects, implant of peripheral nerve stimulators to stimulate the occipital nerve is a promising treatment modality for patients with chronic headache who present with features of occipital neuralgia. However, wider use of this treatment modality is subject to further studies.
- 26 May 2020
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 21 (7) , 1317-1318
Hearing the Call for Therapeutic Ultrasound
- 26 May 2020
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 21 (7) , 1317-1318
Hearing the Call for Therapeutic Ultrasound
- 13 June 2018
- Published by Wiley in Pain Practice
- Vol. 19 (1) , 52-56
A Case Report of Combined Ultrasound and Fluoroscopic‐Guided Percutaneous Radiofrequency Lesioning of the Obturator and Femoral Articular Branches in the Treatment of Persistent Hip Pain in a Pediatric Patient
Hip denervation comprising radiofrequency lesioning of the obturator and femoral articular branches is used in adults with refractory hip pain who are not surgical candidates. Persistent hip pain infrequently occurs in pediatric patients and there is limited data on the safety and efficacy of this procedure in a pediatric population. We provide a case report of a successful ultrasound and fluoroscopic‐guided hip denervation procedure in an 11‐year old female with persistent right hip pain after septic arthritis refractory to conservative and surgical management strategies. At an 18‐ week follow‐up, hip denervation provided improvement in pain, mobility, and reduced opioid consumption by 20%.
- 13 June 2018
- Published by Wiley in Pain Practice
- Vol. 19 (1) , 52-56
A Case Report of Combined Ultrasound and Fluoroscopic‐Guided Percutaneous Radiofrequency Lesioning of the Obturator and Femoral Articular Branches in the Treatment of Persistent Hip Pain in a Pediatric Patient
Hip denervation comprising radiofrequency lesioning of the obturator and femoral articular branches is used in adults with refractory hip pain who are not surgical candidates. Persistent hip pain infrequently occurs in pediatric patients and there is limited data on the safety and efficacy of this procedure in a pediatric population. We provide a case report of a successful ultrasound and fluoroscopic‐guided hip denervation procedure in an 11‐year old female with persistent right hip pain after septic arthritis refractory to conservative and surgical management strategies. At an 18‐ week follow‐up, hip denervation provided improvement in pain, mobility, and reduced opioid consumption by 20%.